Esperion Therapeutics (ESPR) Cash from Operations (2012 - 2026)

Esperion Therapeutics has reported Cash from Operations for 15 years, with the latest figure at 27722000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 22.51% year-over-year to 27722000.0; the trailing twelve-month figure through Mar 2026 stood at 18187000.0 (up 81.83% YoY), and the FY2025 full-year result was 13093000.0, up 44.65% from the prior year.
• Cash from Operations for Q1 2026 stood at 27722000.0, down from 45243000.0 in the prior quarter.
• The five-year high for Cash from Operations was 53828000.0 in Q1 2024, with the low at 54356000.0 in Q1 2023.
• Historically, Cash from Operations has averaged 22046058.82 across 5 years, with a median of 31422000.0 in 2025.
• The largest YoY upside for Cash from Operations was 229.44% in 2025 against a maximum downside of 336.11% in 2025.
• Esperion Therapeutics' Cash from Operations stood at 42472000.0 in 2022, then increased by 12.75% to 37056000.0 in 2023, then grew by 5.68% to 34952000.0 in 2024, then surged by 229.44% to 45243000.0 in 2025, then tumbled by 161.27% to 27722000.0 in 2026.
• The last three Cash from Operations figures came in at 27722000.0 (Q1 2026), 45243000.0 (Q4 2025), and 4286000.0 (Q3 2025), per Business Quant data.